Dr. Wang received her MD from FuDan University Medical School followed by PhD training in Pharmacology at Mayo Graduate School. Currently, Dr. Wang is a full Professor in the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic Rochester. Dr. Wang's research has been focused on the application of multiple omics technology joined with a cell-based model system which she developed that consists of 300 lymphoblastoid cell lines (LCLs) with extensive high through put genomic data to study mechanisms of cancer biology and therapy, including both chemotherapy and radiation therapy. At mechanistic level, her research has also focused on understanding regulation of the PI3K-AKT and AMPK pathways and their impact on response to drug therapy. As a Co-PI for the past decade, she led the functional genomics activities within the Mayo-NIH Pharmacogenomics Research Network (PGRN) grant that included the PGx of breast cancer. She has been involved in and has led functional genomic studies related to many clinical translational breast cancer studies that helped to identify and understand biomarkers associated with clinical response to endocrine therapy and chemotherapy in breast cancer patients. She is also leading a program at Mayo that is developing patient derived xenografts (PDX) using breast cancer and prostate cancer biopsy samples collected from prospective trials with the intention to use those PDX models to help facilitating drug development and to understand mechanisms associated with resistance to therapy.